AIBT · Aibotics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | $0 | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $1.85M | $1.63M | $616.7K | $1.88M | $14.2K | - |
| Total Operating Expenses | $1.85M | $1.63M | $616.7K | $1.88M | $14.2K | - |
| D&A | $0 | $498 | $998 | $1.0K | $249 | $548 |
| Operating Income | ($1.84M) | ($1.63M) | ($616.7K) | ($1.88M) | ($14.2K) | - |
| Interest Expense | $226.9K | $213.5K | $564.6K | $868.3K | $0 | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($2.22M) | ($1.85M) | ($1.18M) | ($2.75M) | ($16.0K) | ($242.2K) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $255.9K | $185.1K | $279.1K | $1.27M | $1.27M | $57.4K |
| Accounts Receivable | - | - | - | - | - | $0 |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $270.1K | $185.1K | $279.1K | $385.9K | $1.27M | $455.5K |
| Total Assets | $874.7K | $1.46M | $2.22M | $387.4K | $1.27M | $455.5K |
| Current Liabilities | $4.79M | $4.85M | $4.25M | $764.5K | $306.4K | $1.1K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $4.83M | $4.85M | $4.25M | $1.28M | $930.0K | $1.1K |
| Stockholders' Equity | ($3.96M) | ($3.39M) | ($2.03M) | ($891.3K) | $340.0K | $454.3K |
| Retained Earnings | ($13.03M) | ($10.81M) | ($8.96M) | ($5.60M) | ($2.85M) | $371.0K |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($458.2K) | ($259.0K) | ($106.8K) | ($656.6K) | ($235.5K) | ($302.8K) |
| Investing Cash Flow | - | - | $0 | $0 | ($2.7K) | ($349.0K) |
| Financing Cash Flow | $529.1K | $165.0K | $0 | ($225.0K) | $125.0K | - |
| CapEx | - | - | - | $0 | $0 | - |
| Free Cash Flow | - | - | - | ($656.6K) | ($235.5K) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.24 | 14.69 | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -253.3% | -126.9% | -53.2% | -710.2% | -1.3% | -53.2% |
| Return on equity | 56.0% | 54.4% | 58.2% | 308.7% | -4.7% | -53.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.06 | 0.04 | 0.07 | 0.50 | 4.14 | 396.39 |
| Quick ratio | 0.06 | 0.04 | 0.07 | 0.50 | 4.14 | 396.39 |
| Cash ratio | 0.05 | 0.04 | 0.07 | 1.66 | 4.14 | 49.92 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -8.1x | -7.7x | -1.1x | -2.2x | - | - |
| Equity multiplier | -0.22 | -0.43 | -1.09 | -0.43 | 3.74 | 1.00 |
| Liabilities / Assets | 5.53 | 3.33 | 1.91 | 3.30 | 0.73 | 0.00 |
| Efficiency | ||||||
| Asset turnover | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -12.8% | -165.1% | 67.1% | -13089.3% | - | - |
| Net income growth (YoY) | -19.9% | -56.5% | 57.1% | -17065.5% | 93.4% | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -178.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -16.7% | -67.4% | -127.6% | - | -25.2% | -30.3% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-23.22
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing AIBOTICS against the 5 most active filers in the same SIC group.